

in the possible role of the opioid peptide, dynorphin (DYN), and the neuropeptide Y (NPY) neural systems in psychiatric disorders. DYN is involved in psychomimetic and dysphoric effects, whereas NPY has been mainly implicated in the neurobiology of depression and anxiety. We have used *in situ* hybridization histochemistry to monitor the mRNA expression pattern and levels of DYN, NPY, and their receptors in subjects diagnosed with bipolar disorder, major depression, or schizophrenia. Brain areas of interest include the cerebral cortex (anterior cingulate and prefrontal), amygdala, and striatum. The results accumulated thus far indicate a greater abnormality in subjects diagnosed with affective disorders in the expression levels of, e.g., the DYN mRNA in amygdaloid complex or of the NPY-related genes in the cerebral cortex. There are indications of striatal abnormalities in the DYN mRNA expression in schizophrenic subjects. Thus, overall, the DYN and NPY-related genes appear to be more impaired in association with affective disorder than with schizophrenia.

S15.6

Oligodendroglial reduction in the prefrontal cortex in schizophrenia

N.A. Uranova*, D.D. Orlovskaya, V.M. Vostrikov, V.I. Rachmanova

Previously we found ultrastructural signs of apoptosis and necrosis of oligodendroglial cells (Ol) in postmortem prefrontal area 10, layer VI and caudate nucleus in schizophrenia (SCH). We hypothesized that the numerical density (Nv) of Ol might be decreased in schizophrenic brains as compared to control brains. Nv of Ol was estimated by optical disector method in area 10, layer VI and adjacent white matter in 25 cases of SCH (ICD-10 diagnostic criteria) and 20 normal controls. Mean Nv of Ol decreased significantly in layer VI (-32%); and in adjacent white matter (-11%). Three-way ANOVA with diagnosis, age and postmortem delay as independent factors showed a significant effect of the diagnosis on Nv of Ol in both layer VI: $F(1,37)=12.55$, $p=0.001$ and adjacent white matter: $F(1,37)=6.67$, $p=0.014$. The result is consistent with our previous data of a decreased Nv of Ol in area 9, layer VI in SCH in the brain sections from the Stanley Foundation Neuropathology Consortium, and suggests a wide spread pathology of Ol in SCH brain.

Supported by the Theodore and Vada Stanley Foundation.

to be common in bipolar patients and to mask in several cases the disorder of mood. The diagnosis of bipolar disorder has been shown to be difficult in some cases, in particular the mild and the atypical ones. Moreover, the onset of the disorder in childhood or adolescence has been reported to be not rare, and to generate further diagnostic problems.

The impact of long-term lithium monotherapy on the course of bipolar disorder has been found to be often not satisfactory. Several alternative drugs have been introduced in clinical practice, and the choice of the most appropriate drug or combination of drugs in the individual patient has become much more complex. The specific problems posed by the treatment of the depressive phase of bipolar disorder have been recognised. Research has documented that some psychosocial interventions may be a useful addition to pharmacotherapy in bipolar patients. The outcome of bipolar disorder has been proved to be frequently poor, from both the psychopathological and the psychosocial viewpoint, and the social and economic burden of the disorder has been reported to be huge.

The debate about some of the above issues, however, remains open. For instance, it has been argued that the concept of bipolar spectrum lacks an organizing principle and may reduce the reliability of the diagnosis of bipolar disorder. Moreover, the definition of "mood stabiliser" remains controversial, and indeed the mood stabilising properties of the various available drugs are not consistently evaluated by researchers.

The above developments and debate have had only a limited impact on clinical practice worldwide. In fact, the concepts of bipolar spectrum and bipolar II disorder have been incorporated in clinical routine only in a few countries. Long-term treatment of bipolar patients with standard antipsychotics remains a common practice. New mood stabilisers remain underused in many countries (while they are possibly overused in some others), and the popularity of the individual compounds varies significantly from one country to the other. Psychosocial interventions for bipolar disorder are unknown to the majority of psychiatrists around the world. Bipolar patients with psychotic symptoms and a deteriorating course are still likely to receive a diagnosis of schizophrenia in several clinical contexts.

This lecture aims to review the above-mentioned developments and controversies concerning the diagnosis and management of bipolar disorder, and to provide European psychiatrists with a balanced update of currently available scientific evidence and clinical wisdom.

SAL04. Bipolar disorders

SAL04

The diagnosis and management of bipolar disorder: developments and controversies

M. Maj*. *Department of Psychiatry, University of Naples, Italy*

No more than twenty years ago, bipolar disorder was predominantly viewed as a relatively rare condition characterised by periods of euphoria and depression, which was easy to diagnose and to treat, whose treatment was exclusively pharmacological, and whose outcome was usually good.

This perception has changed dramatically in the last two decades. It has become clear that the label "bipolar disorder" actually encompasses a variety of conditions, whose overall lifetime prevalence in the general population may be as high as 5%. The concept of bipolar II disorder has been validated by research; mixed and psychotic forms of bipolar disorder have turned out to be much more frequent than previously believed; the concomitance of alcohol or drug abuse and of anxiety disorders has been found

SAL05. Anxiety

SAL05

Anxiety

J. Zohar. *Israel*

No abstract was available at the time of printing.